Anesiva Announces South Korea FDA Approval Of Adlea(TM) Investigational New Drug Application
Anesiva, Inc. (Nasdaq: ANSV) announced that the South Korea Food and Drug Administration has approved Anesiva’s investigational new drug application for Adlea(TM), the company’s long-acting, site specific, non-opioid drug candidate in Phase 3 clinical development for the management of acute pain following orthopedic surgery. Anesiva plans to initiate a Phase 2 clinical trial of Adlea in patients undergoing arthroscopic shoulder surgery in South Korea this summer.
More: continued here